Skip to Content

Nivolumab in combination with ipilimumab as first-line treatment of patients with NSCLC continues to show an improved overall survival

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top